

(BD Biosciences, San Jose, CA, USA), embedded in paraffin, sectioned, and immunostained for CD31. Endogenous peroxidase activity was blocked by incubation of the latter sections for 20 min with 0.3% H<sub>2</sub>O<sub>2</sub> in methanol, and nonspecific sites were blocked with antibody diluent (Dako Japan, Kyoto, Japan). Sections were then incubated overnight at 4°C with a 1:50 dilution of a rat monoclonal antibody to mouse CD31 (BD Biosciences), washed with PBS, and processed with a Histfine Simple Stain PO (M) kit (Nichirei, Tokyo, Japan) for detection of immune complexes. Sections were counterstained with Mayer's hematoxylin, covered with a coverslip with the use of a permanent mounting medium, and examined with a light microscope (CX41; Olympus, Tokyo, Japan).

### Statistical analysis

Data are presented as means  $\pm$  s.d. or s.e. and were compared by the unpaired Student's *t*-test. A *P* value of  $<0.05$  was considered statistically significant.


## RESULTS

### Induction of cell cycle arrest at M phase but not at G<sub>1</sub>-S in tsFT210 cells by TZT-1027

To examine the effect of TZT-1027 on cell cycle progression, we performed flow cytometric analysis of tsFT210 cells, which express a temperature-sensitive mutant of Cdc2. These mammary carcinoma cells exhibit a normal cell cycle distribution when incubated at the permissive temperature of 32.0°C, but they arrest at G<sub>2</sub> phase as a result of Cdc2 inactivation when incubated at the

nonpermissive temperature of 39.4°C (Figure 2A and B). We synchronised tsFT210 cells at G<sub>2</sub> phase by incubation at 39.4°C for 17 h and then cultured them at 32.0°C for 6 h in the presence of nocodazole (an inhibitor of microtubule polymerisation), TZT-1027, or vehicle (DMSO). In the presence of vehicle alone, the number of cells in G<sub>2</sub> phase decreased markedly and there was a corresponding increase in the number of cells in G<sub>1</sub> phase, indicative of re-entry of cells into the cell cycle (Figure 2C). In contrast, treatment with nocodazole or TZT-1027 prevented the cells from passing through G<sub>2</sub>-M phase (Figure 2D and E). Given that flow cytometric analysis did not distinguish between cells in M phase and those in G<sub>2</sub> phase, we determined the mitotic index of cells by DAPI staining and fluorescence microscopy. Most of the cells released from temperature-induced arrest in the presence of nocodazole manifested condensed chromosomes without a nuclear membrane, yielding a mitotic index of 93%; most of the cells had thus arrested in mitosis (Figure 2D). Most of the cells released from temperature-induced arrest in the presence of TZT-1027 showed similar mitotic figures, yielding a mitotic index of 85% (Figure 2E) and demonstrating that TZT-1027 also inhibits cell cycle progression at mitosis.

We next examined whether TZT-1027 affects the G<sub>1</sub>-S transition. We arrested tsFT210 cells at G<sub>2</sub> phase by incubation at 39.4°C, released the cells into G<sub>1</sub> phase by shifting to the permissive temperature for 6 h, and then incubated them for an additional 6 h in the presence of roscovitine (an inhibitor of CDK2 that prevents cell cycle progression at G<sub>1</sub> phase), TZT-1027, or vehicle (Figure 3). The cells incubated with vehicle passed through G<sub>1</sub> phase and yielded a broad S-phase peak (Figure 3D), whereas those treated with roscovitine did not pass through G<sub>1</sub> phase (Figure 3E). In contrast, TZT-1027 had no effect on passage of the synchronised tsFT210 cells through the G<sub>1</sub>-S transition (Figure 3F). Together,



**Figure 2** Inhibition of tsFT210 cell cycle progression through G<sub>2</sub>-M by TZT-1027. Cells were cultured at the permissive temperature of 32.0°C (A) and then incubated for 17 h at the nonpermissive temperature of 39.4°C (B). They were subsequently released from G<sub>2</sub> arrest by incubation at 32.0°C for 6 h in the presence of DMSO (C), 1  $\mu$ M nocodazole (D), or 2 nM TZT-1027 (E). At each stage of the protocol, cells were analysed for DNA content by staining with propidium iodide and flow cytometry. The 2N and 4N peaks indicate cells in G<sub>0</sub>-G<sub>1</sub> and G<sub>2</sub>-M phases of the cell cycle, respectively. The cells were also stained with DAPI and examined by fluorescence microscopy after treatment with DMSO, nocodazole, or TZT-1027 (lower panels), and the mitotic index (MI) was determined; scale bar, 20  $\mu$ m. Data are representative of at least three independent experiments.

these results indicate that the effect of TZT-1027 on cell cycle progression is specific to M phase.

### Induction of cell cycle arrest at M phase in asynchronous H460 cells by TZT-1027

We next examined whether TZT-1027 induced mitotic arrest in asynchronous H460 human non-small cell lung cancer cells. Flow cytometric analysis revealed that treatment of H460 cells with TZT-1027 for 24 h induced a threefold increase in the proportion of cells with a DNA content of 4N compared with that apparent for

vehicle-treated cells (29.1 vs 8.7%) (Figure 4A and B). Furthermore, DAPI staining revealed that TZT-1027 induced a significant increase in the mitotic index of H460 cells compared with that for the control cells (23.3 vs 4.6%) (Figure 4C and D), indicating that most of the TZT-1027-treated cells with a DNA content of 4N were arrested in M phase rather than in G<sub>2</sub> phase. These observations thus showed that TZT-1027 also induced mitotic arrest in asynchronous H460 cells.


### Radiosensitisation of H460 cells by TZT-1027 *in vitro*

Cells in M phase are more sensitive to radiation than are those in other phases of the cell cycle. Given that exposure of H460 cells to TZT-1027-induced mitotic arrest, we next examined whether this agent might sensitise H460 cells to  $\gamma$ -radiation with the use of a clonogenic assay. H460 cells were incubated for 24 h with 1 nM TZT-1027 or vehicle (DMSO) and then exposed to various doses (0, 2, 4, or 6 Gy) of  $\gamma$ -radiation. The cells were then allowed to form colonies in drug-free medium for 10–14 days. Survival curves revealed that TZT-1027 increased the radiosensitivity of H460 cells, with a DEF of 1.2 (Figure 5A).


To determine whether radiosensitisation by TZT-1027 was reflected by an increase in the proportion of apoptotic cells, we exposed H460 cells to 1 nM TZT-1027 or vehicle for 24 h, treated the cells with various doses (0, 2, 4, or 6 Gy) of radiation, and then incubated them in drug-free medium for an additional 24 h before quantification of apoptosis. Combined treatment with TZT-1027 and 4 or 6 Gy of radiation resulted in a significant increase in the number of apoptotic cells compared with the sum of the values for treatment with drug alone or radiation alone (Figure 5B). TZT-1027 thus promoted radiation-induced apoptosis in H460 cells.

### Radiosensitisation of H460 cells and A549 cells by TZT-1027 *in vivo*


To determine whether the TZT-1027-induced increase in the radiosensitivity of tumour cells observed *in vitro* might also be apparent *in vivo*, we injected H460 cells or A549 human lung



**Figure 3** Lack of effect of TZT-1027 on tsFT210 cell cycle progression through G<sub>1</sub>-S. Exponentially growing tsFT210 cells (A) were arrested in G<sub>2</sub> phase by incubation for 17 h at 39.4°C (B). The cells were incubated at 32.0°C first for 6 h to allow progression to G<sub>1</sub> phase (C) and then for an additional 6 h in the presence of DMSO (D), 50  $\mu$ M roscovitine (E), or 2 nM TZT-1027 (F). At each stage of the protocol, cells were analysed for DNA content by flow cytometry. Data are representative of at least three independent experiments.



**Figure 4** Induction of cell cycle arrest at M phase in H460 cells by TZT-1027. H460 cells were incubated in the presence of 1 nM TZT-1027 or vehicle (DMSO) for 24 h, after which DNA content was measured by flow cytometry (A) and the fraction of cells in G<sub>2</sub>-M phase was determined (B). The cells were also stained with DAPI and examined by fluorescence microscopy (C) and the mitotic index was determined (D). Data in (A) through (C) are representative of at least three independent experiments; data in (D) are means  $\pm$  s.d. of values from three independent experiments. Scale bar in (C), 20  $\mu$ m.



**Figure 5** Sensitisation of H460 cells to  $\gamma$ -radiation by TZT-1027 *in vitro*. **(A)** Clonogenic assay. Cells were incubated with 1 nM TZT-1027 or vehicle (DMSO) for 24 h, exposed to the indicated doses of  $\gamma$ -radiation, and then incubated in drug-free medium for 10–14 days for determination of colony-forming ability. Survival curves were generated after correction of colony formation observed for combined treatment with ionising radiation (IR) and TZT-1027 by that apparent for treatment with TZT-1027 alone. **(B)** Assay of apoptosis. Cells were incubated with 1 nM TZT-1027 or vehicle (DMSO) for 24 h, exposed to various doses (0, 2, 4, or 6 Gy) of  $\gamma$ -radiation, and then incubated for 24 h in drug-free medium. Cells were then fixed and stained with DAPI for determination of the proportion of apoptotic cells by fluorescence microscopy. Data in **(A)** and **(B)** are means  $\pm$  s.d. of values from three independent experiments. *P* values in **(B)** are for comparison of the value for combined treatment with TZT-1027 and radiation vs the sum of the corresponding values for each treatment alone, after correction of all data by the control (DMSO) value.

adenocarcinoma cells into nude mice in order to elicit the formation of solid tumours. The mice were then treated with TZT-1027, radiation, or both modalities. Treatment with TZT-1027 alone (single dose of 0.5 mg kg<sup>-1</sup>) or with radiation alone (single dose of 10 Gy) resulted in relatively small inhibitory effects on tumour growth, whereas combined treatment with both TZT-1027 and radiation exerted a markedly greater inhibitory effect (Figure 6A and B). The tumour GDs induced by treatment with TZT-1027 alone, radiation alone, or both TZT-1027 and radiation were 1.0, 2.6, and 8.8 days, respectively, for H460 cells and 1.4, 4.9, and 12.4 days, respectively, for A549 cells (Table 1). The enhancement factor for the effect of TZT-1027 on the efficacy of radiation was 3.0 for H460 cells and 2.2 for A549 cells, revealing the effect to be greater than additive. No pronounced tissue damage or toxicities such as diarrhoea or weight loss of >10% were observed in mice in any of the four treatment groups (Table 2).

We examined the effects of the treatment protocols on apoptosis in H460 tumours by TUNEL staining of tumour sections. Quantification of the number of apoptotic cells revealed that the combined treatment with radiation and TZT-1027 induced a significant increase in this parameter compared with treatment with radiation or TZT-1027 alone (Figure 6C).


#### Histological appearance of H460 tumours after administration of TZT-1027

Finally, we examined whether an effect of TZT-1027 on tumour vasculature might contribute to the antitumour activity of this drug *in vivo*. Mice harbouring H460 tumours were injected with TZT-1027, and the tumours were excised 4 or 24 h thereafter and examined by hematoxylin-eosin staining (Figure 7A–C) or by immunostaining for the endothelial cell marker CD31 (Figure 7D and E). Tumour capillaries appeared congested, with thrombus formation, and showed a loss of endothelial cells 4 h after administration of TZT-1027 (Figure 7B and E), whereas vessels within viable areas of control tumours were generally not congested and showed an intact normal endothelium (Figure 7A and D). The effects of TZT-1027 on the tumour vasculature appeared selective, given that neither loss of CD31 staining nor

vessel congestion was apparent in the vasculature of surrounding normal tissue after drug treatment (Figure 7E). Extensive necrosis was apparent at the tumour core, with a characteristic thin rim of viable tumour cells remaining at the periphery, 24 h after TZT-1027 administration (Figure 7C). These results were thus indicative of a characteristic antivascular effect of TZT-1027 in the H460 tumour model.

#### DISCUSSION

TZT-1027 is a novel antitumour agent that inhibits microtubule polymerisation and exhibits potent antitumour activity in preclinical models (Miyazaki *et al*, 1995; Kobayashi *et al*, 1997; Natsume *et al*, 2000, 2003, 2006; Otani *et al*, 2000; Watanabe *et al*, 2000, 2006a). We investigated the effect of TZT-1027 on cell cycle progression with the use of tsFT210 cells, which can be synchronised in G<sub>2</sub> phase by incubation at 39.4°C and consequent inactivation of Cdc2 (Osada *et al*, 1997; Tamura *et al*, 1999). The use of these cells allows cell synchronisation without the need for agents that prevent DNA synthesis (such as hydroxyurea or thymidine) or that inhibit formation of the mitotic spindle (such as nocodazole). Although such agents halt cell cycle progression in specific phases of the cycle, they are also toxic and kill a proportion of the treated cells. The tsFT210 cell system is thus suited to sensitive analysis of the effects of new compounds on cell cycle progression without loss of cell viability. We have now shown that tsFT210 cells released from G<sub>2</sub> arrest by incubation at 32.0°C failed to pass through M phase in the presence of TZT-1027. Although previous flow cytometric analysis of exponentially growing tumour cells revealed that TZT-1027 induced a marked increase in the proportion of cells in G<sub>2</sub>-M (Watanabe *et al*, 2000), it was uncertain whether the drug arrested cell cycle progression in G<sub>2</sub> or in mitosis. Our morphological data now indicate that, similar to the effect of nocodazole, TZT-1027 arrested tsFT210 cells in M phase rather than in G<sub>2</sub>, consistent with the mode of action of this new compound. Given that microtubules contribute to various cellular functions in addition to cell division, including intracellular transport and signal transduction (Mollinedo and Gajate,



**Figure 6** Sensitisation of H460 and A549 cells to  $\gamma$ -radiation by TZT-1027 *in vivo*. (**A** and **B**) Evaluation of tumour growth. Nude mice with H460 (**A**) or A549 (**B**) tumour xenografts ( $\sim 200$  to  $250$  mm<sup>3</sup>) were treated with a single intravenous dose of TZT-1027 ( $0.5$  mg kg<sup>-1</sup>), a single dose of  $\gamma$ -radiation ( $10$  Gy), or neither (control) or both modalities, and tumour volume was determined at the indicated times thereafter. Data are means  $\pm$  s.e. for six to eight mice per group. (**C**) Quantification of apoptotic cells in H460 tumour sections by TUNEL staining 14 days after the initiation of treatment as in (**A**). Data are means  $\pm$  s.d. \* $P < 0.05$  vs mice treated with TZT-1027 alone or radiation alone.

**Table 1** Tumour growth delay value

Treatment	H460		A549	
	Days <sup>a</sup>	GD <sup>b</sup>	Days	GD
Control	4.5		5.5	
TZT-1027 alone	5.5	1	6.9	1.4
Radiation alone	7.1	2.6	10.4	4.9
TZT-1027 + Radiation	13.3	8.8	17.9	12.4
Enhancement factor	3		2.2	

<sup>a</sup>Days, the period needed for the sizes of xenografts in each group to reach  $500$  mm<sup>3</sup>;

<sup>b</sup>GD, the additional periods needed for the sizes of xenografts in each group to reach  $500$  mm<sup>3</sup> in addition to the period needed for controls to reach  $500$  mm<sup>3</sup>.

2003), TZT-1027 might also be expected to affect tumour cells in interphase. With the use of synchronised tsFT210 cells, however, we found that TZT-1027 had no effect on progression of cells through the G<sub>1</sub>-S transition of the cell cycle. The effect of TZT-1027 on cell cycle progression thus appears to be specific to M phase.


Given that cells are most sensitive to radiation during mitosis (Sinclair and Morton, 1966; Sinclair, 1968; Pawlik and Keyomarsi,

**Table 2** Body weight loss

Treatment	% of B.W.L. <sup>a</sup>	
	H460	A549
Control	3.6	1.2
TZT-1027 alone	9.9	5.2
Radiation alone	9.7	5.5
TZT-1027+Radiation	8.7	9.9

<sup>a</sup>% of B.W.L. relative body weight loss 7 days after the initiation of the treatment.

2004), we next investigated the possible interaction between TZT-1027 and ionising radiation in human lung cancer cell lines. We found that TZT-1027 increased the sensitivity of H460 cells to  $\gamma$ -radiation *in vitro*. The proportion of H460 cells in mitotic phase at the time of irradiation was increased by TZT-1027 treatment, consistent with the notion that this effect contributes to the observed radiosensitisation induced by this drug. TZT-1027 was previously shown to induce apoptosis in several tumour cell lines (Watanabe *et al*, 2000). Although the relation between apoptosis and radiosensitivity is controversial (Lawrence *et al*, 2001; Pawlik and Keyomarsi, 2004), we showed that treatment of H460 cells with



**Figure 7** Histological analysis of H460 tumours after treatment with TZT-1027. Mice bearing H460 tumour xenografts were treated with a single dose of TZT-1027 ( $2.0 \text{ mg kg}^{-1}$ ), and the tumours were excised at various times thereafter and either stained with hematoxylin-eosin (**A–C**) or immunostained for CD31 (**D and E**). (**A and D**) Control sections of an untreated tumour showing normal capillaries with an intact endothelium and viable tumour cells. (**B and E**) Sections of a tumour removed 4 h after administration of TZT-1027. Vascular congestion, with pink deposits of fibrin, and loss of endothelial cells as well as diffuse tumour cell degeneration are apparent in (**b**). Dark immunostaining of intact endothelium (arrows) is apparent in surrounding normal connective tissue, whereas little staining of endothelial cells was observed in the core (**C**) of the tumour (**E**). (**C**) Section of a tumour removed 24 h after TZT-1027 administration, showing extensive central necrosis (N) and a rim of viable cells (V). Scale bars:  $50 \mu\text{m}$  (**A and B**),  $100 \mu\text{m}$  (**C**), and  $200 \mu\text{m}$  (**D and E**).

TZT-1027 before irradiation induced a marked increase in the proportion of apoptotic cells compared with that apparent with radiation alone. These results thus suggested that potentiation of apoptosis contributed to radiosensitisation by TZT-1027.

Combined treatment with radiation and a single administration of TZT-1027 also inhibited the growth of tumours formed by H460 or A549 cells *in vivo* to a greater extent than did either treatment alone. Tumour microenvironmental factors, such as the vascular supply, are important determinants of sensitivity to radiation therapy *in vivo*. The ability of microtubule-targeting agents to induce a rapid shutdown of the existing tumour vasculature has been recognised by their designation as vascular-targeting agents (VTAs) (Jordan and Wilson, 2004). Treatment with VTAs such as ZD6126 and combretastatin A-4-P typically results in the destruction of large areas of a tumour, with surviving cells remaining only at the tumour periphery (Dark *et al.*, 1997; Blakey *et al.*, 2002). These peripheral viable tumour cells presumably derive their nutritional support from nearby normal blood vessels that are not responsive to VTA treatment (Li *et al.*, 1998; Siemann and Rojiani, 2002). Such support together with a rapid upregulation of angiogenic factors such as vascular endothelial growth factor may directly facilitate the growth and expansion of the remaining tumour cells (Wachsberger *et al.*, 2003; Thorpe, 2004). Given that these residual tumour cells are likely well oxygenated (Wachsberger *et al.*, 2003), they are an ideal target for radiation therapy. Several studies have recently shown that treatment with VTAs enhances the therapeutic effect of radiotherapy (Li *et al.*, 1998; Siemann and Rojiani, 2002, 2005; Horsman and Murata, 2003; Masunaga *et al.*, 2004), consistent with the idea that the components of such combination therapy act in a complementary manner, with VTAs attacking the poorly oxygenated cell population in the central region of tumours and radiation killing the well-oxygenated proliferating cells at the tumour periphery (Li *et al.*, 1998; Siemann and Rojiani, 2002; Wachsberger *et al.*, 2003). TZT-1027 was previously shown to increase vascular permeability and to induce a decrease in tumour blood flow followed by a marked increase in tissue necrosis in the central

region of tumour xenografts (Otani *et al.*, 2000; Watanabe *et al.*, 2006b). We have now shown that TZT-1027 treatment resulted in congestion and occlusion of tumour blood vessels followed by extensive necrosis of the tumour core, with only a thin rim of viable tumour cells remaining, in the H460 tumour model, suggesting that TZT-1027 acts as a VTA. The action of TZT-1027 as a VTA might thus contribute to the radiosensitising effect observed *in vivo* in the present study.

The clinical use of microtubule-interfering agents such as taxanes in combination with radiation has been successful in improving local tumour control. However, taxanes are often of limited efficacy because of the development of cellular resistance such as that mediated by P-glycoprotein-dependent drug efflux (Goodin *et al.*, 2004). The action of TZT-1027 has been suggested to be less affected by multidrug resistance factors, including overexpression of P-glycoprotein, than that of other tubulin inhibitors (Watanabe *et al.*, 2006a), suggesting that TZT-1027 may be effective in the treatment of taxane-refractory tumours. Further investigations are thus warranted to examine the combined effects of TZT-1027 and ionising radiation on drug-resistant tumour cells. Whether TZT-1027 enhances the tumour response to clinically relevant fractionated doses of radiation such as 2 Gy per fraction also warrants further study.

In conclusion, we have found that the inhibitory effect of TZT-1027 on cell cycle progression is highly specific to M phase. Moreover, TZT-1027 enhanced the effects of radiation on human cancer cells both *in vitro* and in animal models *in vivo*. These preclinical results provide a rationale for future clinical investigations of the therapeutic efficacy of TZT-1027 in combination with radiotherapy.

#### ACKNOWLEDGEMENTS

We thank H Kakeya for providing tsFT210 cells as well as M Kobayashi, T Natsume, E Hatashita, Y Yamada, and S Ono for technical assistance.

REFERENCES

Blakey DC, Westwood FR, Walker M, Hughes GD, Davis PD, Ashton SE, Ryan AJ (2002) Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. *Clin Cancer Res* 8: 1974-1983

Choy H, Yee L, Cole BF (1995) Combined-modality therapy for advanced non-small cell lung cancer: paclitaxel and thoracic irradiation. *Semin Oncol* 22: 38-44

Dark GG, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ (1997) Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. *Cancer Res* 57: 1829-1834

de Jonge MJ, van der Gaast A, Planting AS, van Doorn L, Lems A, Boot I, Wanders J, Satomi M, Verweij J (2005) Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. *Clin Cancer Res* 11: 3806-3813

Edelstein MP, Wolfe III LA, Duch DS (1996) Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. *Semin Oncol* 23: 41-47

Goodin S, Kane MP, Rubin EH (2004) Epothilones: mechanism of action and biologic activity. *J Clin Oncol* 22: 2015-2025

Greystoke A, Blagden S, Thomas AL, Scott E, Attard G, Molife R, Vidal L, Pacey S, Sarkar D, Jenner A, De-Bono JS, Steward W (2006) A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. *Ann Oncol* 17: 1313-1319

Hofstetter B, Vuong V, Broggin-Tenzer A, Bodis S, Ciernik IF, Fabbro D, Wartmann M, Folkers G, Pruschy M (2005) Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells *in vitro* and *in vivo*. *Clin Cancer Res* 11: 1588-1596

Horsman MR, Murata R (2003) Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. *Int J Radiat Oncol Biol Phys* 57: 1047-1055

Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. *Nat Rev Cancer* 4: 253-265

Kim JC, Kim JS, Saha D, Cao Q, Shyr Y, Choy H (2003) Potential radiation-sensitizing effect of semisynthetic epothilone B in human lung cancer cells. *Radiother Oncol* 68: 305-313

Kim JS, Amorino GP, Pyo H, Cao Q, Price JO, Choy H (2001) The novel taxane analogs, BMS-184476 and BMS-188797, potentiate the effects of radiation therapy *in vitro* and *in vivo* against human lung cancer cells. *Int J Radiat Oncol Biol Phys* 51: 525-534

Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K, Tsukagoshi S (1997) Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. *Jpn J Cancer Res* 88: 316-327

Lawrence TS, Davis MA, Hough A, Rehemtulla A (2001) The role of apoptosis in 2',2'-difluoro-2'-deoxycytidine (gemcitabine)-mediated radiosensitization. *Clin Cancer Res* 7: 314-319

Li L, Rojiani A, Siemann DW (1998) Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. *Int J Radiat Oncol Biol Phys* 42: 899-903

Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB (1994) *In vitro* studies of Taxol as a radiation sensitizer in human tumor cells. *J Natl Cancer Inst* 86: 441-446

Masanaga S, Sakurai Y, Suzuki M, Nagata K, Maruhashi A, Kinash Y, Ono K (2004) Combination of the vascular targeting agent ZD6126 with boron neutron capture therapy. *Int J Radiat Oncol Biol Phys* 60: 920-927

Miyazaki K, Kobayashi M, Natsume T, Gondo M, Mikami T, Sakakibara K, Tsukagoshi S (1995) Synthesis and antitumor activity of novel dolastatin 10 analogs. *Chem Pharm Bull (Tokyo)* 43: 1706-1718

Mollinedo F, Gajate C (2003) Microtubules, microtubule-interfering agents and apoptosis. *Apoptosis* 8: 413-450

Natsume T, Watanabe J, Horiuchi T, Kobayashi M (2006) Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs. *Anticancer Res* 26: 1145-1151

Natsume T, Watanabe J, Koh Y, Fujio N, Ohe Y, Horiuchi T, Saijo N, Nishio K, Kobayashi M (2003) Antitumor activity of TZT-1027 (Soblidotin)

against vascular endothelial growth factor-secreting human lung cancer *in vivo*. *Cancer Sci* 94: 826-833

Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M (2000) Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. *Jpn J Cancer Res* 91: 737-747

Osada H, Cui CB, Onose R, Hanaoka F (1997) Screening of cell cycle inhibitors from microbial metabolites by a bioassay using a mouse cdc2 mutant cell line, tsFT210. *Bioorg Med Chem* 5: 193-203

Otani M, Natsume T, Watanabe J, Kobayashi M, Murakoshi M, Mikami T, Nakayama T (2000) TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. *Jpn J Cancer Res* 91: 837-844

Pawlik TM, Keyomarsi K (2004) Role of cell cycle in mediating sensitivity to radiotherapy. *Int J Radiat Oncol Biol Phys* 59: 928-942

Schoffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R, Satomi M (2004) Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. *Ann Oncol* 15: 671-679

Siemann DW, Rojiani AM (2002) Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. *Int J Radiat Oncol Biol Phys* 53: 164-171

Siemann DW, Rojiani AM (2005) The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. *Int J Radiat Oncol Biol Phys* 62: 846-853

Simoens C, Vermorken JB, Korst AE, Pauwels B, De Pooter CM, Pattyn GG, Lambrechts HA, Breillout F, Lardon F (2006) Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, *in vitro*. *Cancer Chemother Pharmacol* 58: 210-218

Sinclair WK (1968) Cyclic x-ray responses in mammalian cells *in vitro*. *Radiat Res* 33: 620-643

Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. *Radiat Res* 29: 450-474

Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M (2007) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. *Cancer Chemother Pharmacol* (in press)

Tamura K, Rice RL, Wipf P, Lazo JS (1999) Dual G<sub>1</sub> and G<sub>2</sub>/M phase inhibition by SC-alpha alpha delta 9, a combinatorially derived Cdc25 phosphatase inhibitor. *Oncogene* 18: 6989-6996

Thorpe PE (2004) Vascular targeting agents as cancer therapeutics. *Clin Cancer Res* 10: 415-427

Vokes EE, Haraf DJ, Masters GA, Hoffman PC, Drinkard LC, Ferguson M, Olak J, Watson S, Golomb HM (1996) Vinorelbine (Navelbine), cisplatin, and concomitant radiation therapy for advanced malignancies of the chest: a Phase I study. *Semin Oncol* 23: 48-52

Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. *Clin Cancer Res* 9: 1957-1971

Watanabe J, Minami M, Kobayashi M, Natsume T, Watanabe J, Horiuchi T, Kobayashi M (2006a) Antitumor activity of TZT-1027 (Soblidotin). *Anticancer Res* 26: 1973-1981

Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M (2000) Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. *Apoptosis* 5: 345-353

Watanabe J, Natsume T, Kobayashi M (2006b) Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma. *Cancer Sci* 97: 1410-1416

Workman P, Twentymen P, Balkwill F, Balmain A, Chaplin D, Double J, Embleton J, Newell D, Raymond R, Stables J, Stephens T, Wallace J (1998) United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia 2nd edn. *Br J Cancer* 77: 1-10

ORIGINAL ARTICLE

Toshio Shimizu · Taroh Satoh · Kenji Tamura  
Tomohiro Ozaki · Isamu Okamoto · Masahiro Fukuoka  
Kazuhiko Nakagawa

## Oxaliplatin/fluorouracil/leucovorin (FOLFOX4 and modified FOLFOX6) in patients with refractory or advanced colorectal cancer: post-approval Japanese population experience

Received: August 16, 2006 / Accepted: January 10, 2007

### Abstract

**Background.** The oxaliplatin/fluorouracil/leucovorin (FOLFOX regimen) is an effective and generally well-tolerated regimen in Western clinical studies of advanced colorectal cancer. In Japan, oxaliplatin was approved in April 2005.

**Methods.** To evaluate the objective tumor responses and feasibility (toxicities) of FOLFOX regimens (FOLFOX4 and modified FOLFOX6, mFOLFOX6) in a predominantly Japanese population with refractory or advanced colorectal cancer in Japan, 51 consecutive patients with histologically confirmed metastatic colon or rectum cancer who were treated between April 2005 and March 2006 were enrolled in a retrospective study. FOLFOX4 was used for treatment in 39% (first-line, 45%) of these patients, and mFOLFOX6 was used for treatment in 61% (first-line, 61%). Tumor responses were assessed radiologically, and toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 regarding toxicities other than peripheral sensory neuropathy.

**Results.** The objective response rates (in those who underwent first- or second-line therapy) were 50.0% and 8.7%, respectively. The tumor control rate (partial response [PR] + stable disease [SD]) was 80.4%. There were no toxicity-related deaths. Neutropenia grade 3 was experienced in 20% of patients, and often caused delay in the subsequent treatment course. Mild to moderate cumulative peripheral sensory neuropathy affected 78% of patients. The incidence of hypersensitivity reactions to oxaliplatin in our study was lower than that in reported in Western countries.

**Conclusion.** Both FOLFOX regimens have good efficacy in refractory or advanced colorectal cancer in a Japanese population, with an acceptable overall toxicity profile.

**Key words** Oxaliplatin · FOLFOX · Colorectal cancer · Japanese population

### Introduction

In 2000, it has reported that colorectal cancer (CRC) was diagnosed in more than 90 000 patients per year in Japan, resulting in 36 000 deaths per year.

Colorectal cancer accounts for 10% to 15% of all cancers and is the third leading cause of cancer-related death in Western countries. Approximately one-half of all patients develop metastatic disease. The prognosis for these patients is poor, although palliative chemotherapy has been shown to be able to prolong survival and improve the quality of life over best supportive care. For many years, the treatment of metastatic colorectal cancer was restricted to 5-fluorouracil (5FU) and the biomodulation of this agent.<sup>1</sup> Oxaliplatin and irinotecan, combined with continuous infusion of 5FU, significantly improved response rate, progression-free survival (PFS), and overall survival.<sup>2–4</sup> FOLFOX4 (oxaliplatin and leucovorin [LV] 5FU2) is more active than LV5FU2 alone, and has also shown superiority over IFL (irinotecan, FU bolus, leucovorin). Oxaliplatin (L-OHP), a new third-generation 1,2-DACH-platinum derivative, has a mechanism of action similar to that of other platinum derivatives.<sup>5–9</sup> However, its spectrum of antitumor activity in tumor models differs from those of cisplatin and carboplatin. In addition, it has also been observed to demonstrate activity against cisplatin-resistant colon carcinoma cell lines.<sup>10</sup> In addition, experimental data have shown synergistic activity of the oxaliplatin/FU combination. The clinical toxicity of oxaliplatin is also distinct from that of other platinum drugs: it has no renal toxicity and minimal hematotoxicity; it causes both a reversible acute, cold-related dysesthesia and a dose-limiting cumulative peripheral sensory neuropathy that usually regresses rapidly after treatment withdrawal. The recent availability of five active chemotherapeutic agents has doubled the median overall survival for metastatic CRC from 10 to 20 months.

T. Shimizu (✉) · K. Tamura · T. Ozaki  
Department of Medical Oncology, Kinki University Nara Hospital,  
1248-1 Otoda-cho, Ikoma, Nara 630-0293, Japan  
Tel. +81-743-77-0880; Fax +81-743-77-0890  
e-mail: tshimizu@nara.med.kindai.ac.jp

T. Satoh · I. Okamoto · M. Fukuoka · K. Nakagawa  
Department of Medical Oncology, Kinki University School of  
Medicine, Osaka, Japan


Three combinations have shown excellent first-line efficacy in phase III trials – IFL with bevacizumab, FOLFOX, and FOLFIRI – however, neither of these combinations is clearly superior. Our clinical practice in Japan has been guided in a major way by extrapolation from the results of clinical trials conducted mainly in Western countries. To evaluate the value of FOLFOX regimens in the treatment of refractory or advanced CRC, a retrospective analysis study was designed to assess the feasibility (toxicities) and efficacy of combining oxaliplatin with the LV5FU2 schedule in a Japanese population. We herein report our experience with two FOLFOX regimens (FOLFOX4 and modified [m] FOLFOX6) in patients with advanced CRC, specifically, the toxicities and objective tumor response rates obtained.

## Patients and methods

A retrospective analysis study was conducted at Kinki University Hospital in 51 consecutive patients with histologically confirmed metastatic colon or rectum cancer who were treated between April 2005 and March 2006. The primary objectives were to assess the feasibility (toxicities) and efficacy of two FOLFOX regimens (FOLFOX4 and mFOLFOX6) in a Japanese population. FOLFOX4 is a regimen comprising oxaliplatin 85 mg/m<sup>2</sup> as a 2-h infusion (day 1); LV 100 mg/m<sup>2</sup> per day as a 2-h infusion (days 1 and 2); followed by a 5FU bolus 400 mg/m<sup>2</sup> per day and 5FU 600 mg/m<sup>2</sup> per day as a 22-h infusion (days 1 and 2). mFOLFOX6 is a regimen also comprising oxaliplatin 85 mg/m<sup>2</sup> as a 2-h infusion

(day 1), LV 200 mg/m<sup>2</sup> per day as a 2-h infusion (day 1), followed by a 5FU bolus 400 mg/m<sup>2</sup> (day 1) and 5FU 2400 mg/m<sup>2</sup> per day as a 46-h infusion (days 1 to 2). These therapies were administered on day 1 and repeated on day 2 of a 14-day treatment cycle. Routine antiemetic prophylaxis with a serotonin (5-HT<sub>3</sub>) antagonist (granisetron) and dexamethasone was given (Fig. 1). The use of implantable ports and infusion pumps allowed chemotherapy to be administered on an outpatient basis in some cases. Treatment was continued until either disease progression, the occurrence of unacceptable toxicity, or the patient refused further treatment. Toxicity was graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 regarding toxicities other than peripheral sensory neuropathy and by following the oxaliplatin-specific scale (DEB-NTC). The definitions in the oxaliplatin-specific scale, which was developed as a specific scoring scale for oxaliplatin-inducing peripheral sensory neuropathy, are as follows: grade 1, transient dysesthesia and/or paresthesia lasting for less than 7 days; grade 2, transient dysesthesia and/or paresthesia lasting for 7 days or longer; and grade 3, dysesthesia and/or paresthesia with pain or function impairment that interferes with activities of daily living (such as difficulty with fastening buttons and writing). The response of measurable target lesions to treatment was objectively evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria after each four cycles of treatment. Complete response (CR) was defined as the disappearance of all disease. Partial response (PR) was defined as at least a 30% reduction in the sum of the longest diameters of all measured lesions by at least 4 weeks. Progressive disease (PD) was defined as an increase in lesions by 20%

Fig. 1. Treatment schema for FOLFOX4 and mFOLFOX6 regimens. LV, leucovorin; 5-FU, 5-fluorouracil; L-OHP, oxaliplatin; c.i., continuous infusion





or greater, or the appearance of new lesions. Responses not falling into any of these categories were classified as stable disease (SD).

## Results

### Patient characteristics

A total of 51 patients with a median age of 61 years (range, 34–78 years) with refractory or advanced CRC were retrospectively analyzed. The patients' characteristics are listed in Table 1. Patients were treated with the FOLFOX4 (39%) or mFOLFOX6 regimens (61%). Twenty-eight patients (55%; FOLFOX4, 9; mFOLFOX6, 19) were treated in a first-line setting, and 23 patients (45%; FOLFOX4, 11; mFOLFOX6, 12) were treated in a second-line setting. Since April 2005, 4 months prior to beginning this study, we have used the FOLFOX4 regimen for inpatients, and from that time we selected the mFOLFOX6 regimen for all patients in the outpatient setting. The total number of chemotherapy cycles administered was 384, with a median of 8 cycles per patient (range, 1–12 cycles). The median dose intensity (actual/planned dose) was 93.4% for oxaliplatin and 100% for 5FU in the FOLFOX4 group and 91.2% for oxaliplatin and 94.8% for 5FU in the mFOLFOX6 group. The median dose intensity of oxaliplatin was 37 mg/m<sup>2</sup> per week (range, 31–42 mg/m<sup>2</sup> per week) in the FOLFOX4 group and 34 mg/m<sup>2</sup> per week (range, 23–42 mg/m<sup>2</sup> per week) in the mFOLFOX6 group.

### Hematological toxicity

Several pertinent hematological toxicities are listed in Table 2, shown with numbers of patients who experienced

them. The onset of neutropenia typically occurred between 10 and 14 days after treatment. Grade 3 and 4 neutropenia was observed in 20% of patients, with neutropenic fever being uncommon. Neutropenia often caused delay in the start of a subsequent treatment course. In all, 88 (23%) of 384 cycles were delayed due to toxicity, most commonly hematological: 64 (17%) for neutropenia and 24 (6%) for neurotoxicity. Using our administration schedule, no thrombocytopenia of over grade 3 was observed to develop. In addition, only one patient developed grade 3 anemia with transfusion.

### Nonhematological toxicity

The most common nonhematological adverse effects of the FOLFOX regimens were peripheral neuropathy and lethargy (fatigue). These effects are listed in Table 3. Two patients experienced grade 2 hypersensitivity reactions (rash/hives, erythema, and one patient also experienced vomiting) during the administration of oxaliplatin. The symptoms rapidly resolved, in a few minutes, on symptomatic treatment (termination of infusion, use of steroids, and antagonists of type 1 and 2 histamine receptors). In using successful strategies over the next treatment courses (slowing the infusion rate, increasing the doses of steroids, and dose reduction of oxaliplatin), both patients were able to tolerate rechallenge of oxaliplatin, and one patient achieved a partial response. Peripheral neurotoxicity, characterized by paresthesia in a symmetric, glove-and-stocking distribution, occurred in 40 (78%) patients and there was no grade over 3.

Whenever the number of treatment cycles increases, neuropathy, within grade 2 level, tends to increase. The incidence of neurotoxicity along with the number of treatment cycles is listed in Table 4. Cold-related dysesthesia

**Table 1.** Characteristics of the study patients

Characteristics	n = 51
Sex, male/female	28/23
Age, years, median (range)	61 (34–78)
Performance status (ECOG), 0/1/2	19/25/7
Primary tumor, colon/rectum/rectosigmoid	28/20/3
Adjuvant therapy, +/-	18/33
Previous irinotecan therapy, +/-	15/36
Site of metastases, lung/liver/LN/peritoneum	22/21/18/7
FOLFOX4/mFOLFOX6	20/31
First-line/second-line	28/23
Dose reduction: +/-	7/44

ECOG, Eastern Cooperative Oncology Group; LN, distant lymph nodes

**Table 2.** Hematological toxicity (CTCAE V3.0)

	n = 51					
	Grade 1	Grade 2	Grade 3	Grade 4	All grades	Grade ≥3
Leucocytopenia	17	16	1	0	67%	2%
Neutropenia	18	15	9	1	84%	20%
Anemia	19	8	1	0	55%	2%
Thrombocytopenia	23	5	0	0	55%	0%

Table 3. Nonhematological toxicity (CTCAE V3.0)\*

	n = 51					
	Grade 1	Grade 2	Grade 3	Grade 4	All grades	Grade $\geq 3$
Anorexia	16	2	2	0	39%	4%
Nausea	13	2	2	0	33%	4%
Vomiting	5	2	2	0	18%	4%
Mucositis	10	1	2	0	25%	4%
Febrile neutropenia	-	-	0	0	0%	-
Hand-foot syndrome	2	0	0	0	4%	-
Pigmentation	4	0	-	-	7%	-
Allergy	0	2	-	-	4%	-
Lethargy	13	4	0	0	33%	-
AST/ALT elevation	22	2	0	0	47%	-
Diarrhea	8	2	2	0	23%	4%
Sensory neuropathy	31	9	0	0	78%	-

\*Other than sensory neuropathy

Table 4. Incidence of neurotoxicity in FOLFOX regimens

Grade	1-4 Cycles (n = 9)			5-8 Cycles (n = 28)			9-12 Cycles (n = 14)			All cycles (n = 51)		
	1	2	3	1	2	3	1	2	3	1	2	3
Sensory neuropathy	5	0	0	19	2	0	7	7	0	31	9	0
	56%	0%	0%	68%	7%	0%	50%	50%	0%	60%	18%	0%

Grade	The oxaliplatin-specific scale (DEB-NTC)			
	0	1	2	3
Dysesthesia and/or paresthesia	No abnormality	Transient dysesthesia and/or paresthesia lasting less than 7 days	Transient dysesthesia and/or paresthesia lasting 7 days or more	Dysesthesia and/or paresthesia with pain or function impairment that interferes with activities of daily living

was reported in 31 patients (61%). Paresthesia lasting 7 days or longer (grade 2) occurred in 9 patients (18%). Peripheral neuropathy appeared in two forms. In the first form, an acute, transient, cold-exacerbated dysesthesia or paresthesia occurred shortly after the administration of oxaliplatin; it affected the hands, feet, perioral area, and throat; and typically lasted for several days after drug administration. In the second form, a delayed-onset, cumulative, dose-related peripheral neuropathy was characterized by paresthesias affecting the hands and feet that did not remit between cycles of treatment. Investigators also reported pharyngolaryngeal dysesthesia in only one patient; however, no patients had a laryngospasm-like syndrome.

Overall, 7 of the 51 patients (14%) required dose modification during treatment; dose reduction was required for oxaliplatin alone in 4 patients, for 5FU alone in 2 patients and for both agents in 1 patient. The majority of dose reductions were by one level (reduction to 65 mg/m<sup>2</sup> oxaliplatin and/or 75% of the starting dose of 5FU). No patients required a second-level dose reduction. The adverse events most commonly leading to dose reduction were neurotoxicity (1 patient in FOLFOX4 and 3 patients in mFOLFOLFOX6) and diarrhea (2 patients in mFOLFOLFOX6). In addition, 2 patients in the mFOLFOLFOX6 setting underwent a dose reduction of oxaliplatin due to allergic reaction. The most common reason for treatment discontinuation was PD.

#### Antitumor activity

All 51 patients were able to be evaluated for response. Objective responses are listed in Table 5 and Table 6. There was no complete response. The overall objective response rates (in those who underwent first-line or second-line therapy) were 50.0% and 8.7%, respectively (Table 6). Stable disease was achieved in 49% of patients. The tumor control rate (PR + SD) was 80.4%.

#### Discussion

The recent advent of several new agents for the treatment of metastatic CRC has markedly enhanced the therapeutic armamentarium for this disease. Oxaliplatin in combination with infusional 5FU in the FOLFOX regimens has been shown to be effective in achieving improved response rate, time to progression, and survival time compared with 5FU/LV. In addition, recent large clinical phase III studies (N9741, EFC4584, GERCOR) showed that combination chemotherapy regimens, including irinotecan and oxaliplatin, markedly improved response rates and prolonged median survival over those seen with 5FU/LV,<sup>11-13</sup> and these combination chemotherapy regimens have supplanted 5FU/LV as a standard systemic approach for metastatic CRC. The median survival time (MST) has been gradually pro-

**Table 5.** Objective responses - (1)

FOLFOX4 (n = 20)		SD	PD	NE
CR	PR			
0	5 (25%) First-line, 3; second-line, 2	12 (60%)	3 (15%)	0
mFOLFOX6 (n = 31)				
0	11 (35.5%) First-line, 11; second-line, 0	13 (41.9%)	7 (22.6%)	0

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable

**Table 6.** Objective responses - (2)

First-line (n = 28)		SD	PD	NE
CR	PR			
0	14 (50%) FOLFOX4, 3; mFOLFOX6, 11	11 (39.3%)	3 (10.7%)	0
Second-line (n = 23)				
0	2 (8.7%) FOLFOX4, 2	14 (60.9%)	7 (30.4%)	0

CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; NE, not evaluable

longed through the use of 5FU/LV with irinotecan and oxaliplatin. Currently, with the addition of molecular targeted agents, an MST of over 20 months has been reported.

Since April 2005, and the approval of oxaliplatin in Japan, clinical practice in this country has been conducted in a major way by extrapolation from the results of clinical trials conducted mainly in large Western phase III studies. The results of the present retrospective study demonstrate the efficacy and feasibility of FOLFOX regimens (FOLFOX4 and mFOLFOX6) as treatment for patients with advanced CRC in the Japanese population, as has been shown in Western populations. In this retrospective analysis study in a Japanese population, neutropenia grade 3/4 occurred in 20% of the patients who were assigned to receive oxaliplatin, but it was nonfebrile, whereas grade 3/4 vomiting and mucositis affected only 4% of the patients, while diarrhea affected 4%.

Lethargy has been described as the most frequent adverse event of the mFOLFOX6 regimen in a recent report by Braun et al.<sup>14</sup> In our study, 17 (33%) patients experienced lethargy similar to general fatigue symptoms.

The cumulative dose-limiting toxicity of oxaliplatin is peripheral sensory neuropathy, which reportedly occurs in about 70%–80% of patients; it typically resolves a few months after discontinuation of treatment, and may be exacerbated by cold stimulation. In our series, paresthesia lasting 7 days or longer was observed in 18% of patients and led to an oxaliplatin dose reduction for four patients after they had received a minimum of seven cycles (or at least 4 months) of chemotherapy.

The mechanism of this neurotoxicity has been elucidated to be as follows: the increased neuronal excitability is due to the action of oxaliplatin on voltage-gated sodium channels through the chelation of calcium by the oxaliplatin

metabolite. The prevention of this neurotoxicity is a major goal, taking in to account the wide indications of this drug. Various different approaches have been either previously studied or are now being evaluated, based on pathogenic or practical concepts: (1) modification of the administration schedule; (2) substances acting upon sodium channels, such as calcium-magnesium, carbamazepine, gabapentine, venlafaxine; (3) detoxifying agents and antioxidants, such as glutathione, amifostine, alpha-lipoic acid, tocopherol; (4) substances used in other kinds of neuropathy, such as glutamine and alpha-lipoic acid; (5) neurotrophic factors, such as nerve growth factor (NGF), LIF; and (6) oxaliplatin analogs, with a DACH platin; without oxalate. Calcium-magnesium infusion appears to be an efficient and safe approach.

In this study, after September 2005, 32 patients (63%) were administered calcium-magnesium infusion for the prevention of the oxaliplatin-related neurotoxicity. Further studies are necessary for a better understanding and prevention of this potentially severe neurotoxicity.

In terms of antitumor activity, although the response rate (RR) in our population was slightly lower in comparison to that in previous Western clinical studies,<sup>11–13</sup> both of the oxaliplatin-based regimens demonstrated a promising objective RR in the first-line setting (50.0%) and in the tumor control rate (80.4%).

In a GERCOR study, the median survival was 21.5 months in 109 patients allocated to FOLFIRI then FOLFOX6 versus 20.6 months in 111 patients allocated to FOLFOX6 then FOLFIRI ( $P = 0.99$ ). In first-line therapy, FOLFIRI achieved a 56% RR and 8.5-month median PFS, versus FOLFOX6, which achieved a 54% RR and 8.0-month median PFS ( $P = 0.26$ ). Second-line FOLFIRI achieved a 4% RR and 2.5-month median PFS, versus

FOLFOX6, which achieved a 15% RR and 4.2-month PFS.<sup>13</sup> Although our study could not evaluate enough data for PFS and MST due to the short observation period after the approval of oxaliplatin in Japan, both the FOLFOX regimens we used seem to be beneficial as first-line and second-line therapy for refractory or advanced CRC in a Japanese population, with an overall response rate which is comparable to Western figures regarding first-line and second-line therapy. FOLFOX6 is the most useful of the FOLFOX regimens because it is simple and can be administered on an outpatient basis. When we use oxaliplatin in FOLFOX regimens, because 85 mg/m<sup>2</sup> is the approved dose for usage in Japan, the treatment is adapted for this dose, even in the mFOLFOX6 regimen.

In conclusion, the FOLFOX regimens we used were found to demonstrate good efficacy as chemotherapy regimens in our population, with an acceptable overall toxicity profile. However, attention must be paid to the occurrence of peripheral sensory neuropathy, which may influence a patient's quality of life, while also limiting the continuation of such treatment.

## References

- Poon MA, O'Connell MJ, Moertel CG, et al. (1989) Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. *J Clin Oncol* 7:1407-1418
- Levi F, Zidani R, Misset JL (1997) Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer: International Organization for Cancer Chronotherapy. *Lancet* 350:681-686
- Giacchetti S, Perpoint B, Zidani R, et al. (2000) Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 18:136-147
- Douillard JY, Cunningham D, Roth AD, et al. (2000) Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 355:1041-1047
- Machover D, Diaz-Rubio E, de Gramont A, et al. (1996) Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. *Ann Oncol* 7:95-98
- Levi F, Perpoint B, Garufi C, et al. (1993) Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. *Eur J Cancer* 29A:1280-1284
- Diaz-Rubio E, Sastre J, Zaniboni A, et al. (1998) Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. *Ann Oncol* 9:105-108
- Becouarn Y, Ychou M, Ducreux M, et al. (1998) A phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. *J Clin Oncol* 8:2739-2744
- de Gramont A, Vignoud J, Tournigand C, et al. (1997) Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. *Eur J Cancer* 33:214-219
- Raymond E, Buquet-Fagot C, Djelloul S, et al. (1997) Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast, and ovarian cancers. *Anticancer Drugs* 8:876-885
- Goldberg RM, Sargent DJ, Alberts SR, et al. (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. *J Clin Oncol* 22:23-30
- de Gramont A, Figuer A, Bonetti A, et al. (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol* 18:2938-2947
- Tournigand C, Andre T, de Gramont A, et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol* 22:229-237
- Braun MS, Adab F, Seymour MT, et al. (2003) Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer. *Br J Cancer* 89:1155-1158

## Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses

Kenji Tamura · Kazuhiko Nakagawa · Takayasu Kurata · Taroh Satoh · Toshiji Nogami · Koji Takeda · Shigeki Mitsuoka · Naruo Yoshimura · Shinzoh Kudoh · Shunichi Negoro · Masahiro Fukuoka

Received: 27 July 2006 / Accepted: 30 October 2006 / Published online: 30 November 2006  
© Springer-Verlag 2006

### Abstract

**Purpose** To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of TZT-1027 (soblidotin), a dolastatin 10 analogue, in Japanese patients with advanced solid tumors when administered on days 1 and 8 in 3-week courses.

**Methods** Eligible patients had advanced solid tumors that failed to respond to standard therapy or for which no standard therapy was available, and also met the following criteria: prior chemotherapy  $\leq 2$  regimens, Eastern Cooperative Oncology Group (ECOG) performance status  $\leq 1$ , and acceptable organ function. The MTD was defined as the highest dose at which no more than one of six patients experienced a DLT during course 1. Pharmacokinetic samples were collected in courses 1 and 2.

**Results** Eighteen patients were enrolled in the present study. Three doses (1.5, 1.65, and 1.8 mg/m<sup>2</sup>) were

evaluated. Neutropenia was the principal DLT at doses of 1.65 and 1.8 mg/m<sup>2</sup>. In addition, one patient also experienced grade 3 pneumonia with neutropenia, and another patient experienced grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia as DLTs at 1.65 mg/m<sup>2</sup>. Phlebitis, the most frequent nonhematological toxicity, was improved by administration of additional saline after TZT-1027 administration. The MTD was 1.5 mg/m<sup>2</sup>, at which DLT was not observed in a total of nine patients. The pharmacokinetic profile did not differ from that for the European population. One patient with metastatic esophageal cancer achieved partial response, and each of two patients with non-small cell lung cancer had a minor response.

**Conclusions** When TZT-1027 was administered on days 1 and 8 in 3-week courses to Japanese patients, the MTD was 1.5 mg/m<sup>2</sup> and was lower than the value of 2.4 mg/m<sup>2</sup> in European patients. However, antitumor activity was observed at low doses. TZT-1027 was tolerated well at the MTD, without grade 3 nonhematological toxicities or neutropenia up to grade 2. TZT-1027 is a promising new tubulin polymerization inhibitor that requires further investigation in phase II studies.

**Keywords** Dolastatin · TZT-1027 · Phase I · Antitubulin · Solid tumors

K. Tamura · K. Nakagawa · T. Kurata · T. Satoh · T. Nogami · M. Fukuoka  
Department of Medical Oncology,  
Kinki University School of Medicine, Osaka, Japan

K. Takeda · S. Negoro  
Department of Clinical Oncology,  
Osaka City General Hospital, Osaka, Japan

S. Mitsuoka · N. Yoshimura · S. Kudoh  
Department of Respiratory Medicine,  
Osaka City University Medical School, Osaka, Japan

K. Tamura (✉)  
Department of Medical Oncology,  
Kinki University School of Medicine,  
Nara Hospital, 1248-1, Otoda, Ikoma,  
Nara 630-0293, Japan  
e-mail: ktamura@nara.med.kindai.ac.jp

### Introduction

TZT-1027 (*N*<sup>2</sup>-(*N,N*-dimethyl-L-valyl)-*N*-[(1*S*,2*R*)-2-methoxy-4-[(2*S*)-2-[(1*R*,2*R*)-1-methoxy-2-methyl-3-oxo-3-[(2-phenylethyl)amino]propyl]-1-pyrrolidinyl]-1-[(1*S*)-1-methylpropyl]-4-oxobutyl]-*N*-methyl-L-valinamide) is a

synthesized analogue of dolastatin 10, a compound isolated from the marine mollusk *Dolabella auricularia* [9, 17]. The chemical structures of TZT-1027 and dolastatin 10 are shown in Fig. 1.

In *in vitro* studies, TZT-1027 exhibited time-dependent cytotoxicity superior to that of other antitumor agents against a variety of murine and human tumor cell lines [19]. TZT-1027 also exhibited antitumor activity against p-glycoprotein (p-gp)-overexpressing and breast cancer resistant protein (BCRP) positive cell lines established from colon cancer H116 and lung cancer PC-6, and was more potent than vincristine, paclitaxel, and docetaxel. The efficacy of TZT-1027 has been attributed to its inhibitory activity on tubulin polymerization. TZT-1027, believed to interact with tubulin in the same domain as the vinca alkaloid-binding region, inhibits the polymerization of microtubule proteins and the binding of GTP to tubulin [12]. In *in vivo* studies, intravenous injection of TZT-1027 has been shown to potently inhibit the growth of P388 leukemic cells and several solid tumors in mice and to increase life span, with efficacy superior or comparable to that of reference agents, dolastatin 10, cisplatin, vincristine, and 5-fluorouracil [4, 7]. In the xenograft models, furthermore, TZT-1027 reduced intratumoral blood perfusion from 1 to later than 24 h after administration, thus leading to hemorrhagic necrosis of tumor [5, 11, 15]. TZT-1027 exerts antitumor activity through direct cytotoxicity, as well as selective blockade of tumor blood flow, resulting in remarkable antitumor activity. In animal toxicology studies, TZT-1027 had no or little neurotoxic potential in marked contrast to vincristine and paclitaxel which are antimicrotubule agents that have exhibited peripheral neurotoxicity in controlled animal studies [14]. When doses of TZT-1027

were increased, on the other hand, myocardial toxicity was observed in rats and monkeys.

In Japan, a single-dose phase I study was conducted at doses up to 1.35 mg/m<sup>2</sup>, but did not reach the MTD. The major toxicity was neutropenia, and nonhematological toxicities included alopecia, malaise, and anorexia. Therefore, a repeated-dose study of TZT-1027 on days 1, 8, and 15 in 4-week courses followed the single-dose study in Japan. Toxicities were similar, with leucopenia and neutropenia as major toxicities. All episodes of grade 4 neutropenia occurred at doses of 1.5 mg/m<sup>2</sup> or higher. Nonhematological toxicities were mild and did not exceed grade 2 in most patients. Neutropenia was observed as a DLT [13, 20], and the recommended dose was 1.8 mg/m<sup>2</sup>. In Europe, three phase I studies were conducted. A repeated-dose study of TZT-1027 according to the administration schedule on days 1 and 8 in 3-week courses was performed in the Netherlands. This schedule was chosen based on the previous phase I study in Japan, in which TZT-1027 had been administered on days 1, 8, and 15; however, several patients could not receive TZT-1027 on day 15 due to neutropenia; the dose of TZT-1027 was escalated to 2.7 mg/m<sup>2</sup>, with neutropenia and infusion arm pain as DLTs. The recommended dose for phase II studies of TZT-1027 was 2.4 mg/m<sup>2</sup> [2]. Phase II studies are ongoing according to this schedule. Two other administration schedules on day 1 in a 3-week course and on day 1 in a 3- to 4-week course were tested in Germany and Hungary, respectively. In the German study, DLTs—including neutropenia, fatigue, and short-lasting, reversible peripheral neurotoxic syndrome—were observed at 3.0 mg/m<sup>2</sup>. On the other hand, the Hungarian study, enrolling exclusively patients with non-small cell lung cancer, was conducted at doses up to 5.6 mg/m<sup>2</sup> [6, 18]. In these studies, the major toxicities were neutropenia, nausea, vomiting, constipation, alopecia, and injection site pain. The pharmacokinetics of TZT-1027 in these studies appeared linear. The rate of TZT-1027 binding to  $\alpha$ 1-acid glycoprotein, a major plasma protein, was ~95%. In all studies, several patients exhibited a tumor reduction.

Preclinical and clinical data indicated that a suitable administration schedule for the present study would be days 1 and 8 in 3-week courses. The purposes of the present phase I study were to assess the DLTs, to determine the MTD, to observe preliminary antitumor activity, and to study the pharmacokinetics of TZT-1027 that was administered intravenously over 60 min on days 1 and 8 in 3-week courses in Japanese patients with advanced solid tumors. The electrocardiogram (ECG), including QTc interval prolongation, was assessed to estimate cardiovascular side effects.




Fig. 1 Structural formulae of TZT-1027 and dolastatin 10

## Patients and methods

### Study design

The present study, an open-label, dose-escalating, three-institution phase I study, was conducted in Japanese patients with solid tumors to assess the DLTs, to determine the MTD and preliminary antitumor activity, and to examine pharmacokinetics. A starting dose of 1.8 mg/m<sup>2</sup> was chosen, since this is the recommended dose for the phase II study based on the previous phase I study in Japan, and TZT-1027 was expected to be effective at this dose.

After the MTD was decided, TZT-1027 was administered to three patients at the MTD level to confirm the appropriate recommended dose for phase II studies. TZT-1027 was given intravenously over 60 min with 250 ml of saline on days 1 and 8 in 3-week courses. The present study and the written consent form were approved by the Institutional Review Board. All patients provided informed consent before study entry. The present study was conducted in accordance with the Good Clinical Practice Guidelines as issued by the International Conference on Harmonization and the Declaration of Helsinki.

### Patient eligibility

Patients with histologically or cytologically confirmed solid tumors, which were refractory to standard therapy or for which no effective therapy was available, were eligible to participate in the present study. Other inclusion criteria included the following: no prior chemotherapy or radiotherapy within 4 weeks of study entry (within 6 weeks for nitrosoureas, carboplatin, and mitomycin C; and within 2 weeks for local radiotherapy); not more than two previous regimens of chemotherapy; no previous wide-field radiotherapy to >25% of the bone marrow; age 20–74 years; ECOG performance status, 0 or 1; life expectancy, at least 2 months; adequate bone marrow: hemoglobin  $\geq$  8.5 g/dl, absolute neutrophil count (ANC)  $\geq$  1,500/mm<sup>3</sup>, platelet count  $\geq$  100,000/mm<sup>3</sup>; and normal hepatic functions [serum bilirubin  $\leq$  1.5 mg/dl, and serum aspartate aminotransferase (ALT) and alanine aminotransferase (AST)  $\leq$  2.5 times the upper limit of normal (ULN), respectively]; and renal function (serum creatinine  $\leq$  lower limit of normal). The left ventricular ejection fraction (LVEF), measured by ultrasound cardiography (UCG), had to be  $\geq$  60%. Patients with symptomatic brain metastases or known extensive bone marrow invasion were excluded.

### Treatment and dose escalation

The dose escalation plan consisted of doses of 1.5, 1.65, and 1.8 mg/m<sup>2</sup>. At least three patients were evaluated for the MTD at each dose. If one DLT was observed in a cohort, a total of six patients were enrolled at that dose. The dose escalation was discontinued when two or more of six patients experienced a DLT. The MTD was defined as the highest dose at which no more than one of six patients experienced a DLT during course 1.

The DLT was defined as follows: (a) grade 4 neutropenia with fever ( $>38.0^{\circ}\text{C}$ ) or lasting 5 days or longer; (b) platelet count  $<$  25,000/mm<sup>3</sup>; (c) grade 3/4 nonhematological toxicity excluding nausea and vomiting; (d) grade 3/4 nausea and vomiting with intensive support care; (e) inability to receive TZT-1027 on day 8 in course 1, which was defined as ANC  $<$  1,000/mm<sup>3</sup>, platelet count  $<$  100,000/mm<sup>3</sup>, a DLT by day 8, or the investigator or subinvestigator assessed it to be difficult to initiate administration; and (f) inability to start course 2 up to day 29. Treatment was resumed when meeting all the following criteria: (a) ANC  $\geq$  1,500/mm<sup>3</sup>; (b) platelets  $\geq$  100,000/mm<sup>3</sup>; (c) total bilirubin  $\leq$  1.5 mg/dl; (d) serum creatinine  $\leq$  ULN.

Patients were withdrawn from the present study when they exhibited disease progression or the next course had to be delayed for more than 2 weeks due to any toxicity. The patients were subsequently treated at the dose one level below the level at which the DLT occurred. Toxicity was assessed using the National Cancer Institute Common Toxicity Criteria (version 2.0).

### Treatment assessment

Baseline assessment, including a complete medical history, physical examination, vital signs, ECOG performance status, blood counts, serum biochemistry, and urinalysis, was conducted to assess patient eligibility and had to be completed within 7 days before the start of treatment. Routine biochemistry, hematology, and urinalysis were performed weekly during the treatment course and within 72 h prior to its start. ECG, as well as blood pressure and pulse rate monitoring were performed immediately before and at the end of drip infusion on days 1 and 8 and on day 2 in courses 1 and 2, as well as at the end of the study. The QT interval was corrected for heart rate (QTc) with Bazett's formula ( $\text{QTc} = \text{QT}/\text{RR}^{0.5}$ ). LVEF was performed every two courses. Tumor response was evaluated after every course by RECIST.

## Pharmacokinetic sampling and assay

The pharmacokinetics of TZT-1027 were evaluated on day 1 in courses 1 and 2. Blood samples were collected immediately before drip infusion, at 30 min after the start of the drip infusion, at the end of the drip infusion, and at 30 min and 1, 2, 4, 6, 8, and 23 h after drip infusion. Urine was collected at the following intervals: 0–6 h and 6–24 h after the start of drip infusion. All blood samples were centrifuged immediately after sampling at  $1,200\times g$  for 15 min at  $4^{\circ}\text{C}$ , and the plasma was stored at  $\leq -20^{\circ}\text{C}$  until analysis. Concentrations of TZT-1027 in plasma and urine were determined according to a validated method of high-performance liquid chromatography/mass spectrometry. The lower limit of quantitation was set to 0.25 ng/ml.

## Pharmacokinetic analysis

Pharmacokinetic analysis of the individual plasma and urine concentration data was made using standard model-independent (noncompartmental) methods (WinNonlin Professional 4.0.1; Pharsight Co., Mountain View, CA). The pharmacokinetic parameters included area under the plasma concentration–time curve extrapolated to infinity ( $\text{AUC}_{\text{inf}}$ ) calculated using the linear trapezoidal rule and maximum observed plasma concentration ( $C_{\text{max}}$ ). Total clearance ( $\text{Cl}_{\text{inf}}$ ) was calculated as  $\text{dose}/\text{AUC}_{\text{inf}}$ . Volume of distribution at steady state ( $V_{\text{ss}}$ ) was calculated using clearance and mean residence time. The terminal elimination half-life ( $T_{1/2}$ ) was calculated using concentration data in the terminal log-linear phase. All computations used the actual sampling times. Pharmacokinetic variables are reported as mean  $\pm$  SD. The nadir for ANC was used to assess the relationships between hematological toxicity and pharmacokinetic parameters ( $\text{AUC}_{\text{inf}}$  and  $C_{\text{max}}$ ).

## Results

## General

Eighteen patients, whose characteristics are shown in Table 1, underwent 35 courses of TZT-1027 (median 2; range 1–5) at three doses (Table 2). All 18 patients were assessable for toxicity in course 1. Almost all patients had already received two regimens of chemotherapy. Sixteen patients (89%) had previously received cisplatin or carboplatin therapy, and 12 patients (67%) paclitaxel or docetaxel therapy. Six patients (33%) had previously received radiotherapy.

**Table 1** Patient characteristics

Characteristics	Number of patients
Number of patients (evaluable)	18 (18)
Age, years; median (range)	66 (47–74)
Gender	
Males	16
Females	2
Performance status (ECOG)	
0	2
1	16
Prior treatments	
Chemotherapy	18
Number of regimens	
1	2
2	16
Containing platinum	16
Containing taxane	12
Radiotherapy	6
Tumor types	
Lung	12
Thymoma	2
Rectal	1
Gastric	1
Esophageal	1
Schwannoma	1

Non-small cell lung cancer (NSCLC) was the most common tumor type in the present study.

## Dose-limiting toxicity

TZT-1027 was administered at three different doses (Table 2). At the first dose of  $1.8\text{ mg}/\text{m}^2$ , two of four patients experienced the DLTs including febrile neutropenia and grade 4 neutropenia lasting 11 days. Three patients were then treated at a lower dose of  $1.5\text{ mg}/\text{m}^2$ , without DLT. Five patients were then treated at a dose of  $1.65\text{ mg}/\text{m}^2$ . Three of these five patients experienced the DLTs. One patient suffered grade 3 pneumonia with neutropenia. Another patient had grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia. The other patient developed grade 4 neutropenia and required a delay in starting course 2 due to neutropenia. To confirm the MTD, additional six patients were treated at a dose of  $1.5\text{ mg}/\text{m}^2$ , and no DLTs were observed. Therefore, none of nine patients experienced DLT at  $1.5\text{ mg}/\text{m}^2$ . TZT-1027 was well tolerated without grade 3 nonhematological toxicity or neutropenia up to grade 2 (Table 3), confirming that this dose was indeed the MTD.

At  $1.8\text{ mg}/\text{m}^2$ , one patient developed a DLT on day 14 due to febrile neutropenia and was treated with granulocyte colony stimulating factor (G-CSF) and an antibacterial agent; the patient recovered on day 21 and was subsequently withdrawn from the present study based on the investigator's discretion. Another



**Table 2** Dose escalation scheme and DLTs in course 1

Dose (mg/m <sup>2</sup> )	Number of patients	Number of courses	Number of patients with any DLT/number of patients	ANC: <500/mm <sup>3</sup> for >5 days	Febrile neutropenia	Other grade 3–4 nonhematological toxicities	Inability to receive TZT-1027 on day 8	Inability to start course 2 up to day 29
1.5	9	21	0/9	0	0	0	0	0
1.65	5	9	3/5	0	0	1 <sup>a</sup>	1 <sup>b</sup>	1 <sup>c</sup>
1.8	4	5	2/4	1	1	0	0	0

ANC absolute neutrophil count

<sup>a</sup> Patient with grade 3 pneumonia with neutropenia<sup>b</sup> Patient with grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia<sup>c</sup> Patient with grade 4 neutropenia

patient developed a DLT, i.e., grade 4 neutropenia, at 1.8 mg/m<sup>2</sup> and withdrew in course 1 at his own request due to grade 2 nausea and anorexia. At 1.65 mg/m<sup>2</sup>, two patients developed DLTs, had the next course that was delayed due to neutropenia and pneumonia with neutropenia, required G-CSF and/or antibacterial agents, and recovered within 1 week. The dose for these patients was reduced to 1.5 mg/m<sup>2</sup> after course 1, and one of them subsequently required a further dose reduction to 1.35 mg/m<sup>2</sup> due to grade 4 neutropenia in course 2. Another patient developed DLTs at 1.65 mg/m<sup>2</sup>, with grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia, and recovered with enemas, laxatives, and IV fluids. This patient was subsequently withdrawn from the present study based on the investigator's judgment. No treatment-related deaths were observed.

#### Hematological toxicities

Neutropenia was the major DLT of TZT-1027. Hematological toxicities as functions of the total numbers of patients and courses of TZT-1027 are shown in Table 3. Grade 3 or 4 neutropenia was observed at doses of  $\geq 1.65$  mg/m<sup>2</sup>. No significant neutropenia was observed at 1.5 mg/m<sup>2</sup>, although most patients underwent two or more courses. Both anemia and thrombocytopenia were relatively mild. Thrombocytopenia was only grade 1 in intensity and was observed in all five patients. The median time to ANC nadir was 18 days (range 14–22 days).

#### Nonhematological toxicities

Table 4 shows drug-related nonhematological toxicities observed in any course of treatment. The common nonhematological toxicities were infusion reaction (phlebitis, injection site reaction, and infusion arm pain), anorexia, malaise, nausea, vomiting, and constipation. The most frequently observed toxicity was phlebitis. There were no relationship between all nonhematological toxicities and doses.

In the present study, grade 2 phlebitis was observed in 12 of 18 patients almost always on the next day of administration and nearly completely disappeared in several days thereafter without medication. Four patients experienced grade 1 to 2 pain, three of whom had infusion arm pain. None of these patients experienced "redness" and "swelling" and had venous thrombosis subsequent to phlebitis. On the other hand, phlebitis was rarely observed in European studies [2, 6, 18]. In the present study, phlebitis alleviated when the patient underwent additional flushing consisting of

**Table 3** Hematological toxicities

Dose (mg/m <sup>2</sup> )	Number of patients	Number of courses	Number of patients with dose reduction	Neutropenia				Anemia			Thrombocytopenia	
				All courses (course 1)				All courses (course 1)			All courses (course 1)	
				Grade	1	2	3	4	Grade	1	2	3–4
1.5	9	21	0	2 (1)	4 (4)	0	0	3 (4)	5 (4)	0	2 (2)	0
1.65	5	9	2 <sup>a</sup>	2 (2)	0	0	3 (3)	1 (1)	2 (1)	0	1 (1)	0
1.8	4	5	0	0	0	1 (1)	2 (2) <sup>b</sup>	0	2 (2)	0	1 (1)	0

<sup>a</sup> Dose was reduced in one patient twice<sup>b</sup> Febrile neutropenia developed in one patient**Table 4** Nonhematological toxicities

Adverse events	Grade 1	Grade 2	Grade 3	Grade 4
Phlebitis		12		
Anorexia	4	6		
Nausea	3	5		
Alopecia	8			
Malaise	6	1		
Pigmentation disorder	5			
Constipation		3	1	
Vomiting	3	1		
Tenderness	4			
Pain <sup>a</sup>	3	1		
Peripheral neuropathy	1	1	1 <sup>b</sup>	
Injection site reaction	3			
Headache	1	1		
Angiopathy	2			
Diarrhea	2			
Arthralgia	2			
Hematuria	2			
Pyrexia	2			
Pneumonia			1	
Neutropenic infection			1	

Drug-related adverse events (total number of patients: 18)

<sup>a</sup> Three of four patients had infusion arm pain<sup>b</sup> Neuropathy at baseline was grade 1

200–250 ml of saline over 30–60 min following administration of TZT-1027.

Three patients experienced peripheral neuropathy in course 1 at 1.5 to 1.8 mg/m<sup>2</sup>. Grade 1 neuropathy was observed in one patient at 1.8 mg/m<sup>2</sup>. Another patient developed grade 2 neuropathy at 1.5 mg/m<sup>2</sup>; however, dose reduction was not required during course 2. Another patient at 1.65 mg/m<sup>2</sup> worsened from grade 1 neuropathy at baseline to grade 3 neuropathy with grade 3 constipation on day 5, with recovery on day 13 and day 18, respectively; the patient was not retreated. Apart from the above patient, there were three patients with grade 1 neuropathy at base line; their disorder did not worsen during the study period.

One patient at 1.65 mg/m<sup>2</sup> experienced pneumonia with grade 3 neutropenia during course 1, was treated with G-CSF and an antibacterial agent, and recovered within 1 week. Therefore, this patient was treated at

1.5 mg/m<sup>2</sup> but again experienced pneumonia without neutropenia during course 2. The patient recovered within 1 week but was not retreated.

Cardiovascular toxicities such as grade 1 hypertension and ventricular arrhythmia were observed. One patient experienced grade 1 hypertension after the first treatment at 1.65 mg/m<sup>2</sup>. The treatment of this patient was interrupted due to the DLTs including grade 3 constipation, neuropathy, grade 4 neutropenia, and hyponatremia. Another patient in the 1.65 mg/m<sup>2</sup> group sporadically experienced grade 1 ventricular arrhythmia at 1.65 mg/m<sup>2</sup> during the study period. All patients underwent 12-lead electrocardiography (ECG) before and after TZT-1027 administration. The 12-lead electrocardiograms had been evaluated by a medical expert on ECG as well as the investigator. Table 5 shows the QTc intervals after each administration of TZT-1027 in courses 1 and 2. The QTc intervals before administration were compared with those after administration, and no significant QTc prolongation was observed.

#### Pharmacokinetics studies

The pharmacokinetics of TZT-1027 were assessed in all patients on day 1 in course 1 (Table 6). Twelve patients receiving TZT-1027 on day 1 in course 2 were also assessed.  $C_{max}$  and  $AUC_{inf}$  tended to increase with dose. However, no statistically significant difference was found among doses. Renal clearance was a minor route of TZT-1027 elimination, since only 1–5% of the dose was excreted unchanged in urine in the first 24 h after administration. Pharmacokinetic parameters were compared between courses 1 and 2. None of  $Cl_{101}$ ,  $T_{1/2}$ , MRT, and  $V_{ss}$  of TZT-1027 differed between courses 1 and 2 at various doses.

Figure 2 shows that  $Cl_{101}$  tended to decrease with increases in the plasma concentration of  $\alpha 1$ -AGP ( $r = 0.57$ ). The correlation between  $C_{max}$  or  $AUC_{inf}$  and the nadir for ANC were not clear due to the small dose range. No correlation was found between clearance and body surface area (BSA) ( $r = 0.16$ ).

**Table 5** QT and QTc intervals (mean  $\pm$  SD) at baseline and after administration of TZT-1027 on days 1 and 8 in 3-week courses

	Baseline				Course 1				Course 2				
	D1	D2	D8 prior to administration	D8 after administration <sup>a</sup>	D1 after administration <sup>a</sup>	D2	D8 prior to administration	D8 after administration <sup>a</sup>	D1 prior to administration	D1 after administration <sup>a</sup>	D2	D8 prior to administration	D8 after administration <sup>a</sup>
Number of data (n)	18	17	17	17	18	17	17	17	12	12	11	11	11
QT (ms)	356 $\pm$ 24 (320–400)	351 $\pm$ 26 (300–400)	356 $\pm$ 25 (314–400)	370 $\pm$ 24 (320–410)	366 $\pm$ 29 (300–420)	351 $\pm$ 26 (300–400)	356 $\pm$ 25 (314–400)	370 $\pm$ 24 (320–410)	353 $\pm$ 14 (330–380)	374 $\pm$ 20 (350–420)	357 $\pm$ 14 (330–380)	351 $\pm$ 32 (310–400)	366 $\pm$ 20 (330–390)
QTc (ms) <sup>b</sup>	412 $\pm$ 34 (366–473)	424 $\pm$ 21 (396–469)	428 $\pm$ 26 (380–469)	420 $\pm$ 20 (392–454)	410 $\pm$ 27 (373–457)	424 $\pm$ 21 (396–469)	428 $\pm$ 26 (380–469)	420 $\pm$ 20 (392–454)	423 $\pm$ 32 (375–481)	413 $\pm$ 25 (377–461)	422 $\pm$ 24 (385–469)	428 $\pm$ 46 (380–549)	429 $\pm$ 20 (408–463)

D day

<sup>a</sup> At the end of drip infusion<sup>b</sup> Calculated by Bazett's correction

## Response evaluation

Five of 18 patients were considered not to be evaluable because treatment had ended during course 1 for reasons other than disease progression. One patient with esophageal cancer who had previously received cisplatin plus 5-fluorouracil with radiotherapy had a partial response at 1.65 mg/m<sup>2</sup>. Duration of treatment was 14 weeks. Six of 13 patients exhibited prolonged stable disease. Tumor shrink was observed in two of six patients evaluated as SD. A patient with NSCLC underwent five courses at 1.5 mg/m<sup>2</sup> and showed a 21% tumor reduction and a decrease in pleural effusion. Another patient with NSCLC at 1.65 mg/m<sup>2</sup> showed a 27% tumor reduction. Another patient with gastric cancer in the 1.5 mg/m<sup>2</sup> group who had a metastatic subcutaneous mass was evaluated as exhibiting disease progression due to the detection of a new lesion in a cervical lymph node; however, the mass reduced with necrosis on the next day after treatment, and the mass reduction rate was 29%.


## Discussion

Tubulin is a well-established target for anticancer agents. Although available antitubulin agents, including taxanes and vinca alkaloids, are highly effective in cancer therapy, their clinical usefulness is limited due to intrinsic or acquired resistance and systemic toxicities. Thus, it is important to develop new agents targeting at the tubulin/microtubule system that may be effective against tumors resistant to existing anticancer agents and an improved toxicity profile. A number of potent cytotoxic compounds have been discovered over the past decade, and candidate anticancer agents originating from marine life have been examined in human clinical trials. Of these compounds, dolastatin 10 and dolastatin 15 have been extensively evaluated in clinical studies. An analogue of dolastatin 15, cemadotin, underwent several administration schedules of phase I studies and showed a major DLT of neutropenia, apart from cardiac toxicity and hypertension [10]. A dolastatin 15 analogue tasidotin exhibited dose-limiting toxicities including neutropenia, ileus, and elevated transaminase levels [1, 3]. Phase I studies of dolastatin 10 were performed, and its DLT was neutropenia [8, 16].

TZT-1027 is designed with the goal of maintaining potent antitumor activity and reducing the toxicities of the parent compound. In mice, intravenous injection of TZT-1027 showed equivalent or greater efficacy than dolastatin 10. On the basis of the preclinical data, a

**Table 6** Pharmacokinetic parameters of TZT-1027 on day 1 in course 1

Dose (mg/m <sup>2</sup> )	Number of patients	C <sub>max</sub> , ng/ml (mean, cv%)	AUC <sub>inf</sub> , ng h/ml (mean, cv%)	Cl <sub>tot</sub> , l/h/m <sup>2</sup> (mean, cv%)	V <sub>ss</sub> , l/m <sup>2</sup> (mean, (cv%)	T <sub>1/2</sub> , h (mean, cv%)
1.5	9	186.0 (31.1)	427.8 (37.9)	4.2 (48.3)	16.7 (46.1)	5.7 (11.7)
1.65	5	211.3 (29.3)	573.2 (45.4)	3.4 (46.3)	19.2 (20.3)	7.6 (32.8)
1.8	4	200.3 (20.9)	502.8 (10.7)	3.6 (10.4)	22.6 (37.3)	7.4 (30.5)

**Fig. 2** Correlation between  $\alpha 1$ -AGP and the clearance of TZT-1027

repeated-dose study of TZT-1027 on days 1, 8, and 15 was conducted in Japan. The DLT according to the administration schedule was neutropenia. The MTD was determined to be less than 2.1 mg/m<sup>2</sup>, and the recommended dose for phase II studies was considered to be 1.8 mg/m<sup>2</sup> [13, 20]. In that study, however, 14 of 40 patients could not receive TZT-1027 on day 15 on schedule due to toxicities. Therefore, a repeated-dose study on days 1 and 8 in 3-week courses was conducted in patients with solid tumors in the Netherlands, in whom TZT-1027 was escalated to 2.7 mg/m<sup>2</sup>. Consequently, the DLTs were neutropenia and infusion arm pain. The recommended dose for phase II studies of TZT-1027 was determined to be 2.4 mg/m<sup>2</sup>.

In the previous phase I study in the Netherlands, the recommended dose for phase II studies was 2.4 mg/m<sup>2</sup>. Grade 3 neutropenia was observed in only 2 of >39 courses at 2.4 mg/m<sup>2</sup>. To standardize the criterion on performance status with that in the Netherlands study and to exclude the influence of the prior chemotherapy to an extent possible, selection criteria were limited in the present study. The median value for the regimen of pretreatment was two courses in the both present and Netherlands study. Major differences between the present study and the previous study in the Netherlands were predominant types of tumor (NSCLC versus several tumors) and median age (66 versus 53 years old, respectively). The pharmacokinetic profiles of TZT-1027

were similar between the present study and the study in the Netherlands. In the Netherlands study at 1.8 mg/m<sup>2</sup>, AUC<sub>inf</sub>, C<sub>max</sub>, T<sub>1/2</sub>, and Cl<sub>tot</sub> were 728.1 ng h/ml, 240.4 ng/ml, 6.65 h, and 4.7 L/h, respectively. It seems difficult to explain based on PK parameters alone why the MTD in the present study differed from that in the Netherlands. On the other hand, three of four patients in the repeated-dose study on days 1, 8, and 15 in Japan did not receive TZT-1027 on day 8 on schedule due to neutropenia at 2.1 mg/m<sup>2</sup>, and one of four patients at 1.8 mg/m<sup>2</sup> in that study underwent no treatment on day 8 due to neutropenia. Between Japanese and European patients receiving TZT-1027, therefore, a difference appeared to exist especially in the severity of bone marrow toxicity.

In the present study, phlebitis was frequently observed as compared with European studies. No significant difference was found in the administration schedule between the present study and the study in the Netherlands. Other frequent nonhematological toxicities were anorexia, nausea, alopecia, constipation, and malaise similarly to European studies. In contrast to other dolastatin analogues, such as a dolastatin 15 analogue tasidotin, increased ALT or AST was rare.

In a previous study according to an administration schedule on day 1 in 3-week courses in Germany, neurotoxicity as a DLT was observed with two of five patients who were treated above the MTD (2.7 mg/m<sup>2</sup>). Both patients had previously received oxaliplatin [18], leading us to conjecture that oxaliplatin predisposes neurotoxicity. In the present study, no patients had been treated previously with oxaliplatin. The neurotoxic influence of TZT-1027 after oxaliplatin should be considered in preclinical studies.

In contrast to the above dolastatin analogues, little cardiovascular toxicity was observed in the present study. Initial studies of cemadotin, a dolastatin 15 analogue, revealed severe hypertension. In the present study, therefore, we measured blood pressure and pulse rate, and conducted the 12-lead ECG before and after TZT-1027 administration for QT interval determination. There was no significant prolongation of the QTc interval at any time point.

Dose intensity in the present study was lower than that in the European studies. However, a partial